ABVC NASDAQ
ABVC BioPharma, Inc.
1W: -10.6%
1M: +16.8%
3M: -46.8%
YTD: -53.9%
1Y: -66.2%
3Y: +1.0%
5Y: -95.9%
$1.01
-0.01 (-0.98%)
Weekly Expected Move ±10.3%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
26 relationships26
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-10-08
Earliest Filing
2025-01-06
Latest Filing
partner: 13
investor: 8
licensee: 5
Counterparties (Filed by ABVC)
26 relationshipsCompanies named in ABVC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lind Global Fund II, LP | — | investor | Investor entering securities purchase agreements and exercising warrants for common stock | 2025-01-06 | View |
| Lind Global Fund II, LP | — | investor | Investor purchasing shares and warrants via securities purchase agreements and exercising existing warrants. | 2024-11-04 | View |
| AiBtl BioPharma Inc. | — | partner | Entered into a multi-year global licensing agreement for CNS drugs with indications of MDD and ADHD. | 2024-06-25 | View |
| Lind Global Fund II, LP | — | investor | Invested in convertible notes and warrants; exercised warrants for cash and received new warrant. | 2024-05-23 | View |
| Allele Capital Partners, LLC | — | partner | Served as exclusive placement agent for the offering. | 2024-05-23 | View |
| OncoX BioPharma, Inc. | — | licensee | Granted exclusive license to develop and commercialize ABVC's BLEX 404 single-herb botanical drug extract for Triple Neg | 2024-05-15 | View |
| Biolite, Inc. | — | partner | ABVC's affiliate that entered into a separate definitive license agreement with OncoX BioPharma, Inc. | 2024-05-15 | View |
| OncoX BioPharma, Inc. | — | licensee | Granted exclusive license to develop and commercialize ABVC's BLEX 404 single-herb botanical drug extract for pancreatic | 2024-05-09 | View |
| Rgene Corporation | — | partner | Entered into a similar license agreement with OncoX BioPharma, Inc. as an affiliate of ABVC BioPharma, Inc. | 2024-04-17 | View |
| OncoX BioPharma, Inc. | — | licensee | Granted exclusive license to develop and commercialize Maitake Mushroom extract for Non-Small Cell Lung Cancer in North | 2024-04-17 | View |
| BIOFIRST CORPORATION | — | partner | Co-development partner entering a licensing agreement for ophthalmology pipeline products | 2024-03-26 | View |
| ForSeeCon Eye Corporation | — | licensee | Received a global definitive licensing agreement for the Company's and BIOFIRST's ophthalmology pipeline products | 2024-03-26 | View |
| Lind Global Fund II, LP | — | investor | Secured convertible note and warrant investor | 2024-02-29 | View |
| Allele Capital Partners, LLC | — | investor | Served as the exclusive placement agent for the securities offering. | 2024-01-17 | View |
| Lind Global Fund II, LP | — | investor | Issued a secured convertible note and warrants to the Company. | 2023-11-20 | View |
| Allele Capital Partners, LLC | — | partner | Served as the exclusive placement agent for the offering. | 2023-11-20 | View |
| Zhonghui United Technology (Chengdu) Group Co., Ltd. | — | partner | Cooperation agreement entered into regarding transaction terms and share issuance limits. | 2023-09-06 | View |
| Zhonghui United Technology (Chengdu) Group Co., Ltd. | — | partner | Agreement to acquire 20% ownership of a property in Leshan, Sichuan, China in exchange for 370,000 shares of common stoc | 2023-08-17 | View |
| Xinnovation Therapeutics Co., Ltd. | — | licensee | Exclusive license to develop, manufacture, market, and distribute ABV-1504 and ABV-1505 in the Chinese market. | 2023-08-02 | View |
| Lind Global Fund II, LP | — | investor | Investor in a secured convertible note offering | 2023-02-24 | View |
| Allele Capital Partners, LLC | — | investor | Investor in a secured convertible note offering | 2023-02-24 | View |
| Rgene Corporation | — | partner | Counterparty to a Trademark Security Agreement | 2023-02-24 | View |
| BioFirst Corporation | — | partner | Counterparty to a Trademark Security Agreement | 2023-02-24 | View |
| BioLite, Inc. | — | partner | Collaborative agreement for licensing rights to develop and commercialize six compounds with milestone payments and roya | 2022-02-22 | View |
| Lucidaim Co., Ltd. | LCID | partner | Joint venture partner entering into a Joint Venture Agreement with the Company and BioLite Japan K.K. | 2021-10-08 | View |
| BioLite Japan K.K. | — | partner | Japanese corporation entering into a Joint Venture Agreement with the Company and Lucidaim Co., Ltd. | 2021-10-08 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Other Events | View | |
| 2026-08-04 | Other Events | View | |
| 2026-07-02 | Accountant Change; Exhibits | View | |
| 2026-03-27 | Shareholder Vote; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Non-Reliance on Previously Issued Financial Statement | View | |
| 2026-01-16 | Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-09-12 | Changes in Registrant's Certifying Accountant | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-06-04 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-30 | Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View | |
| 2025-05-14 | Notice of Delisting or Transfer; Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-14 | Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View | |
| 2025-05-06 | Notice of Delisting or Transfer; Financial Statements and Exhibits | View | |
| 2025-05-02 | Non-Reliance on Previously Issued Financial Statements | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-30 | Notice of Delisting or Transfer; Unregistered Sales of Equity Securities; Financial Statements and E | View | |
| 2025-04-16 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR